Improving access to evidence-based care, including specialized stroke units, intravenous thrombolysis and thrombectomy in eligible patients with acute ischemic stroke, and medications for secondary prevention, is recommended for optimal stroke outcomes. Yet many patients fail to receive these therapies, even in well-resourced settings.^[@R1],[@R2]^ Various strategies have been proposed to reduce evidence-practice gaps. These include audit and feedback, education and training, and the influence of key opinion leaders and professional groups, often with local tailoring and used in combination.^[@R3]--[@R5]^ However, few studies to evaluate these multicomponent strategies that target clinician behavior within hospitals have been undertaken for stroke. Examples include the Get-With-The-Guidelines--Stroke program and Quality in Acute Stroke Care trial in Australia.^[@R2],[@R6],[@R7]^ There is also a lack of evidence for the use of financial incentives to improve stroke care.^[@R8]^

Within Australia, there are 2 main standard quality improvement activities in hospitals. These include the biennial national audit program (since 2007)^[@R9]^ and the Australian Stroke Clinical Registry (AuSCR; established in 2009),^[@R10]^ which has fewer clinical processes than the audit but is collected on all admitted patients and has a 90-day outcome survey. Feedback to hospitals from these programs includes sending personalized benchmarked reports. Within Queensland, additional strategies have included introduction of financial incentives and use of external quality improvement officers to help local teams develop action plans to address evidence-practice gaps (StrokeLink program). We undertook a project (Stroke123) to assess the real-world effectiveness of the new Queensland quality improvement initiatives against a background of standard activities. The primary hypothesis being tested was that Queensland hospitals eligible for financial incentives and participating in an enhanced StrokeLink program could demonstrate greater adherence to a defined set of acute stroke clinical indicators compared with a historical control period and to other hospitals in Australia.

Methods
=======

Design
------

Details of the Stroke123 study design are outlined in detail elsewhere.^[@R11]^ In brief, a prospective, multicenter, before-and-after study design was used to compare performance across hospitals^[@R12]^ according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.^[@R13]^ We approached all 23 public hospitals in Queensland, which admitted ≥100 patients (age, ≥18 years) with acute stroke or transient ischemic attack per annum. These hospitals all contributed data to AuSCR and previous audit programs.^[@R11]^ Ethics approvals were obtained from Monash University (2013-2058-1867) and Metro South Human Research Ethics Committee (HREC/13/QPAH/31) being the lead ethics committee for the Queensland hospitals. Individual informed consent was not required because this was secondary use of deidentified data. The data underlying the findings are available from the corresponding author on reasonable request.

Interventions
-------------

There were 2 intervention components to change practice: financial incentives and the enhanced StrokeLink program. The financial incentive program implemented from 2012 was developed to provide an incentive payment to increase access to stroke units^[@R14]^ (Methods in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075); Table I in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)). Payments were also contingent on a minimum proportion of data collected within AuSCR.

The enhanced StrokeLink program included a single outreach visit to each hospital where clinical staff participated in a workshop facilitated by a quality improvement officer with a clinical background in nursing or allied health. The StrokeLink program is based on the Plan-Do-Study-Act model.^[@R15]^ That is, benchmarked feedback is provided to clinicians on their hospital performance and they develop action plans to improve the care they provide. A unique aspect of the enhanced program being tested from 2014 was the provision of AuSCR clinical indicator and 90-day patient outcome data from the previous 12 months. Previously, only snapshot retrospective medical record review had been provided from the biennial national audit of 40 medical records (with no long-term patient outcome information).^[@R9]^ Other features were an interactive discussion on actions to overcome local barriers and the provision of ongoing support via telephone or email (Methods in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075); Table II in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)).

The interventions were iteratively added, and, therefore, the study comprised 4 phases: T~0~ (pre-intervention: control) with baseline audit and feedback via StrokeLink (January 2010 to June 2012), T~1~ (intervention 1: addition of financial incentives, July 2012 to March 2014), T~2~ (intervention 2: addition of the enhanced StrokeLink program, March 2014 to November 2014), and T~3~ (post-intervention, November 2014 to December 2015), as outlined in the Figure.^[@R11]^

![Stroke123 data flowchart. Composite score: calculated by dividing the total number of relevant clinical indicators achieved by the sum of eligible indicators. Action plan: structured written plan of agreed strategies to overcome identified local barriers to implementation of the desired practices to improve stroke care. Primary outcome composite score: included all indicators: stroke unit care, if ischemic stroke: intravenous thrombolysis and aspirin within 48 h; mobilized on same or following day of admission, swallow screen/assessment, prescribed antihypertensive agents at discharge, prescribed antithrombotics if an ischemic stroke, evidence that a care plan outlining postdischarge care in the community was developed with the team and the patient (only available for T~1~--T~3~ comparisons). Action plan score: limited to the indicators nominated by hospitals to include in their action plan. National score: 4 indicators collected nationally: stroke unit care, intravenous thrombolysis, prescribed antihypertensive agents at discharge, evidence that a care plan outlining postdischarge care in the community was developed with the team and the patient.](str-50-1525-g001){#F1}

Outcome Measures
----------------

Consistent with other studies in this field, we used composite scores that summarize in a single measure the proportion of all needed care that was given.^[@R16]^ Composite scores were derived from individual patient adherence to the following clinical indicators: treatment in a stroke unit; in acute ischemic stroke, use of intravenous thrombolysis, aspirin \<48 hours, and prescription of antiplatelet/other antithrombotic medication at discharge; early patient mobilization; use of a swallow screen/assessment before feeding; prescription of antihypertensive medication at discharge; and use of a discharge care plan if hospital separation is to the community (not measured in T~0~). Composite scores were calculated by dividing the total number of relevant clinical indicators achieved by the sum of eligible indicators for each comparator cohort.

The primary outcome was for change in composite score from ≤8 indicators collected consistently across hospitals in Queensland during the study periods (primary composite score). Secondary outcomes were the change in the composite score from indicators nominated by the hospitals in their action plans during the same period (action plan score) and the change in the composite score from 4 common national clinical indicators, compared with the change in hospitals in other parts of Australia (national score using receipt of stroke unit care, thrombolysis in acute ischemic stroke, prescription of antihypertensive medication at discharge, and use of a discharge care plan).

Statistical Analysis
--------------------

Analyses were undertaken across the 4 time periods, as described in the published Statistical Analysis Plan (Figure).^[@R11]^ In this pragmatic real-world study, stroke clinical indicator data were from 2 comparable sources. Historical data from Queensland collected using similar methods to AuSCR (ie, minimum set of variables on all admitted patients) before 2012 were matched to the AuSCR, and the data quality was found to be similar (Table III in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)). The main difference was lack of 1 variable in the historical Queensland dataset: care plan outlining postdischarge care in the community developed with the team and the patient. Therefore, our analysis using primary composite score either included 7 (T~0~) or 8 clinical indicators (T~1~--T~3~). To assess for the possibility that the results may have been influenced by 1 clinical indicator missing from the historical period, we conducted a sensitivity analysis excluding use of a discharge care plan from the composite score. The action plan score analysis was limited to 14 hospitals with nominated indicators in their action plans (Table III in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)).

Because of the skewed distribution of composite score data, median (interquartile limits) for all composite scores in each time period is reported, and nonparametric methods or quantile regression analyses were used to measure change in composite score by time period, adjusted for clustering by hospital. Multilevel random-effects logistic regression analysis was used to measure change in adherence to individual clinical indicators by time period at the hospital level. Models were also generated with a test of interaction (time period×location, ie, Queensland versus other Australian hospitals) but without adjustment for patient characteristics as all quality indicators were universally applicable to eligible patients.^[@R17]^ Secondary analyses included adjustment for available data on patient characteristics (age, sex, stroke severity \[ability to walk on admission\], and stroke type) because patient-level factors may explain ≤2% of variability in care.^[@R16]^ Significance was 2 sided (α\<0.05). All statistical analyses were undertaken using Intercooled STATA 12.1 for Windows (Statcorp, College Station; 2014).

Results
=======

The study included 19 of the 23 eligible Queensland hospitals (83%) and 23 others located elsewhere in Australia (Figure). Across the 19 Queensland hospitals, a total of 17 502 patients were evaluated across the time periods, with 4781 in T~0~ and 3815 in T~3~ for the primary analysis. Correspondingly, there were 20 484 patients included across the 23 non-Queensland hospitals during all study periods, including 5903 in T~0~ and 5188 in T~3~ (Figure). Patient characteristics were similar between comparator periods and between Queensland and non-Queensland hospitals (Table IV in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)).

Table [1](#T1){ref-type="table"} shows that the median primary composite score increased from 0.57 (T~0~) to 0.75 (T~3~; *P*\<0.001). In adjusted analyses, there was a 14% improvement in median scores after introduction of financial incentives and this increased to 18% during the full intervention period. These trends attenuated and became nonsignificant in the sensitivity analysis excluding use of a discharge care plan indicator from T~1~ to T~3~ (Table V in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)). In secondary outcome analyses limited to those clinical indicators specifically nominated by participating hospitals (n=14), action plan score medians increased by 5% after introduction of financial incentives (T~0~ compared with T~1~, nonsignificant) and 8% during the whole intervention period (T~0~ compared with T~3~, *P*\<0.05; Table [2](#T2){ref-type="table"}). Finally, limiting the analysis to the 4 common national indicators, the national score increased by 17% (95% CI, 13%--20%) at participating Queensland hospitals but was stable across non-Queensland hospitals (0%; 95% CI, −3% to 3%; Table [3](#T3){ref-type="table"}). Results were consistent in supplementary analyses adjusting for patient characteristics (Table VI in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)). In both intervention hospitals in Queensland and nonintervention hospitals elsewhere, the trends were for improved individual patient indicators during the study period (Table [4](#T4){ref-type="table"}; Table VII in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)).
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Discussion
==========

In this multicenter observational study, substantial improvements were evident across several clinical indicators of hospital performance following implementation of a multicomponent quality improvement program (ie, financial incentives and feeding back data to hospital clinicians through StrokeLink). Improvement was the greatest after a financial incentive to improve stroke unit access was introduced (14% improvement from T~0~ to T~1~). These data suggest that multicomponent and complementary interventions are more effective than single-component interventions to improve systems of stroke care. These findings are in contrast to a recent review in which the authors concluded that there was no compelling evidence that multicomponent interventions were more effective than single-component intervention.^[@R18]^

Our overall finding of an 18% improvement in the primary composite score is large and at the upper limit of the treatment effect for other types of quality improvement interventions assessed in randomized trials.^[@R3]^ However, it appears valid because this improvement occurred against a background of stable performance where conventional passive audit and feedback processes were used in hospitals elsewhere in Australia during the study periods (national score). We acknowledge that baseline adherence to performance indicators in non-Queensland hospitals was larger than in Queensland hospitals (Table VII in the [online-only Data Supplement](https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.118.023075)) and may have influenced the overall comparisons if there were ceiling effects. However, this is unlikely because performance across non-Queensland hospitals remained below achievable benchmarks of top performing hospitals based on 2015 AuSCR data (ranging from 5% below benchmarks for intravenous thrombolysis and 31% below for discharge care plans).^[@R19]^ Overall, the comparator hospitals had small improvements across several individual clinical indicators that were consistent with systematic review evidence of audit and feedback interventions (pooled median 4.3% effect size).^[@R20]^

Reported effects of other hospital-based pay-for-performance interventions have been variable,^[@R8]^ ranging from no effect^[@R21]^ to a 4% to 22% improvement in programs for acute coronary syndrome, heart failure, and pneumonia.^[@R22]^ Success of the Queensland financial incentive program is consistent with the evidence for an implementation strategy led by clinical leaders with support by government in a setting of low baseline performance.^[@R8]^ Although funding mechanisms differ across health systems, the principles of the Queensland financial incentives provide a basis for other countries to establish similar pay-for-performance schemes for increasing access to stroke units.

The association between stroke unit care and patient outcome is undisputed^[@R23]^ and is the cornerstone for providing best-practice care in hospitals. The initial targeting of stroke unit care with financial incentives was associated with concurrent improvements in adherence to some (ie, thrombolysis for acute ischemic stroke and early mobilization), but not all, measured clinical indicators. This evidence is consistent with other research, whereby stroke units are associated with greater adherence to evidence-based processes of care than other models of care.^[@R11],[@R24],[@R25]^

Strategies to improve clinical practice should account for local factors that might inhibit quality improvement.^[@R26]^ In this study, the use of the externally facilitated enhanced StrokeLink program was associated with a nonstatistically significant additive increase in both the primary composite score (4%) and action plan scores (3%) after introduction of financial incentives---an effect size that is consistent with published findings of comparable interventions.^[@R26]^ The other reported system-wide quality improvement intervention based on audit and feedback in stroke is the Get-With-The-Guidelines program.^[@R7]^ This intervention was similar to our baseline quality improvement interventions, but more intensive (quarterly workshops, more education), and did not include feedback of patient-level outcomes. These authors report a composite score increase of 10.5% during 5 years with an annualized increase in the odds of receiving measures in their composite score of 1.18.^[@R7]^ Specific novel components in our intervention that may have contributed to our somewhat better improvement included feedback of long-term patient outcomes and ongoing support provided to hospitals via email and telephone. Because many countries have national registries for monitoring stroke care including longer term patient outcomes,^[@R27]^ our approach to audit and feedback could be replicated whereby feedback of long-term outcomes is incorporated, where feasible.

Strengths of our study include being multicentered, the large sample sizes, and continuous longitudinal data. Only 4 public hospitals in Queensland were excluded because they did not participate in either AuSCR or the enhanced StrokeLink program. Therefore, the included hospitals represented different service levels from small regional to large comprehensive stroke units, strengthening the generalizability of our results. We used historical controls in Queensland and contemporaneous controls from other states in Australia to avoid threats to internal validity.

Limitations of our study include the lack of randomization and the inability to firmly distinguish the effects of the individual intervention components, which was not our aim. Attribution of any changes seen subsequent to an improvement intervention may be complicated by factors other than the intervention that may interfere with the system or disrupt the pattern of data.^[@R28]^ The temporal and additive nature of the observed associations provides confidence in the whole package, as does the lack of change in the national score in other Australian comparator hospitals. We were also conservative in our approach to not overestimate effects in our handling of missing indicator data whereby we assumed the process of care did not occur.

In conclusion, the complementary and iterative interventions tested in this real-world study, comprising financial incentives and externally facilitated feedback of registry data with action planning, led to substantial and clinically relevant improvements in best-practice care. Our interventions are readily transferable. Our study contributes important knowledge that can be used to help improve health systems and clinical services for stroke. The individual components and the combined quality improvement intervention deserve further study and application in other regions and countries.
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